Lycia Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Public

  • Employees
  • 31

Employees

  • Stock Symbol
  • LYCA

Stock Symbol

  • Share Price
  • $33.23
  • (As of Friday Closing)

Lycia Therapeutics General Information

Description

Lycia Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases.

Contact Information

Website
www.lyciatx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 400 East Jamie Court
  • Suite 200
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 400 East Jamie Court
  • Suite 200
  • South San Francisco, CA 94080
  • United States
+1 (650)

Lycia Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lycia Therapeutics Stock Performance

As of 20-Nov-2026, Lycia Therapeutics’s stock price is $33.23. Its current market cap is $1.72B with 52.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$33.23 $31.77 $22.19 - $36.49 $1.72B 52.1M 433K -$1.04

Lycia Therapeutics Financials Summary

As of 30-Jun-2026, Lycia Therapeutics has a trailing 12-month revenue of $4.43M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024
Revenue 4,435 6,741 14,936
EBITDA (33,006) (40,318) (31,474)
Net Income (30,032) (36,460) (26,503)
Total Assets 156,760 97,215 150,911
Total Debt 3,162 2,749 4,771
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lycia Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lycia Therapeutics‘s full profile, request access.

Request a free trial

Lycia Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Lycia Therapeutics‘s full profile, request access.

Request a free trial

Lycia Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Lycia Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of novel thera
Drug Discovery
South San Francisco, CA
31 As of 2026

New Haven, CT
 

Emeryville, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lycia Therapeutics Competitors (7)

One of Lycia Therapeutics’s 7 competitors is Arvinas, a Formerly VC-backed company based in New Haven, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arvinas Formerly VC-backed New Haven, CT
Kyverna Formerly VC-backed Emeryville, CA
Kymera Therapeutics Formerly VC-backed Watertown, MA
Equillium Formerly VC-backed La Jolla, CA
Palleon Pharmaceuticals Venture Capital-Backed Waltham, MA
You’re viewing 5 of 7 competitors. Get the full list »

Lycia Therapeutics Patents

Lycia Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026236399-A1 Anti-transferrin receptor antibodies Pending 07-May-2025
WO-2026015652-A2 Anti-ige antibodies with ph-dependent binding characteristics Pending 10-Jul-2024
WO-2026015652-A3 Anti-ige antibodies with ph-dependent binding characteristics Pending 10-Jul-2024
WO-2026015664-A1 Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige) Pending 10-Jul-2024
AU-2025245050-A1 Lysosomal targeting bifunctional molecules for degradation of thyroid stimulating hormone receptor autoantibodies Pending 28-Mar-2024 A61K47/549
To view Lycia Therapeutics’s complete patent history, request access »

Lycia Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lycia Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lycia Therapeutics‘s full profile, request access.

Request a free trial

Lycia Therapeutics FAQs

  • When was Lycia Therapeutics founded?

    Lycia Therapeutics was founded in 2019.

  • Where is Lycia Therapeutics headquartered?

    Lycia Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of Lycia Therapeutics?

    Lycia Therapeutics has 31 total employees.

  • What industry is Lycia Therapeutics in?

    Lycia Therapeutics’s primary industry is Drug Discovery.

  • Is Lycia Therapeutics a private or public company?

    Lycia Therapeutics is a Public company.

  • What is Lycia Therapeutics’s stock symbol?

    The ticker symbol for Lycia Therapeutics is LYCA.

  • What is the current stock price of Lycia Therapeutics?

    As of 20-Nov-2026 the stock price of Lycia Therapeutics is $33.23.

  • What is the current market cap of Lycia Therapeutics?

    The current market capitalization of Lycia Therapeutics is $1.72B.

  • What is Lycia Therapeutics’s current revenue?

    The trailing twelve month revenue for Lycia Therapeutics is $4.43M.

  • Who are Lycia Therapeutics’s competitors?

    Arvinas, Kyverna, Kymera Therapeutics, Equillium, and Palleon Pharmaceuticals are some of the 7 competitors of Lycia Therapeutics.

  • What is Lycia Therapeutics’s annual earnings per share (EPS)?

    Lycia Therapeutics’s EPS for 12 months was -$1.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process